Michael Carroll joins board of UK's health protection agency
This article was originally published in Scrip
Michael Carroll, of Carrollpharma Consulting, has been appointed to the board of the UK'sHealth Protection Agency. He was formerly UK operations director for Novartis.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.